Primex Pharmaceuticals AG: Next real innovation in paediatric anaesthesia since propofol
Swiss company Primex Pharmaceuticals AG announces the presentation of phase II results of ADV6209 at the 16 th World Congress of Anaesthesiologists.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160831005810/en/
Approximately 60% of children experience significant behavioural stress during perioperative or procedural sedation, making them anxious, frightened, phobic and non-cooperative. The ultimate goal is a safe and effective procedural sedation service.
Professor Hervé Dupont, Head of the Anaesthesiology and Critical Care Medicine Department at Amiens University Hospital, presented the clinical results from the phase II study and his own experiences of ADV6209 in paediatric sedation. The results show the rapid sedative effect with excellent acceptability by paediatric patients in clinical practice as one of the main advantages of the novel formulation.
ADV6209 is an oral solution, and it will be the first paediatric sedative registered in Europe, expected to be on the market next year.
"We are excited to bring the next anaesthetic innovation to the market,” Mr. Alan Knox, Head of Global Marketing at Primex comments. "Anaesthesiologists have been asking for a paediatric sedative that is accepted by children and well tolerated to be used by non-anaesthesiologists. For children, there is a large unmet need for pre-anaesthesia and a huge unmet need for procedural sedation, e.g. in emergency and diagnostic procedures."
Kari Sarvanto, President and Co-Founder of Primex Group, added: “Bringing this new solution to the market will be a major step towards making Primex Pharmaceuticals the leading global anaesthesia pharmaceutical company.”
About Primex Pharmaceuticals
Primex Pharmaceuticals is a fast growing global specialty company spearheading a new lean pharmaceutical business model.
Primex aims to become the leading global innovative Anaesthesia company helping patients undergo a wide range of medical procedures. With a portfolio of strong, trusted anaesthesia products including Recofol N (propofol), and the recent acquisition of a novel oral solution pharmaceutical candidate for paediatric anaesthesiology. Primex Pharmaceuticals will continue to identify and acquire new medications that complete the ‘Triad of Anesthesia’.
Primex Pharmaceuticals' global partner network operates in over 40 countries and reaches a population of nearly one billion. The company is headquartered in Zug, Switzerland; all Primex products are manufactured in the EU. Primex Pharmaceuticals has proven underlying business operations and historically strong revenue growth.
Mr Kari Sarvanto, President
Mobile: +41 796 162 694
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
PIERRE-FABRE23.6.2018 13:02 | pressemeddelelse
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress
SERVIER23.6.2018 10:12 | pressemeddelelse
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho
SOFTOMOTIVE22.6.2018 17:15 | pressemeddelelse
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA
TX-ASCEND-PERFORMANCE22.6.2018 16:02 | pressemeddelelse
Ascend Performance Materials Announces Price Increase for Intermediate Materials
DELTICOM-AG/MOTO-TYRES.C22.6.2018 15:43 | pressemeddelelse
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk
BOEHRINGER-INGELHEIM22.6.2018 14:02 | pressemeddelelse
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum